Trials / Completed
CompletedNCT00902135
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 702 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1b (Betaseron, BAY86-5046) | Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder |
| DRUG | Interferon beta-1b (Betaseron, BAY86-5046) | Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder |
| DRUG | Interferon beta-1b (Betaseron, BAY86-5046) | Interferon beta-1b (Betaferon) |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2013-12-01
- Completion
- 2014-08-01
- First posted
- 2009-05-14
- Last updated
- 2015-07-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00902135. Inclusion in this directory is not an endorsement.